Stabilitech to have oral coronavirus vaccine ready for preclinical evaluation in 3 months

UK biopharma company Stabilitech is developing OraPro-COVID-19,  applying its OraPro technology with the aim of developing a viral vector with six weeks, and having a capsule ready for animal testing within 12 weeks.

The company said, “Because OraPro-COVID19 is thermally stable and in capsules, it can be self-administered orally by patients – this eliminates the queues of people waiting for injections, enabling the world’s most rapid deployment of vaccines. Stabilitech’s OraPro-COVID-19 vaccine development aims to deliver in 3 months an oral vaccine with two unique properties, capsule administration and broad mucosal and systemic immunity.”

More information on the company’s web page.

Comment on this article


W3 Total Cache is currently running in Pro version Development mode.